FilingsTodayRevolution Medicines
At a glance
Revolution Medicines reported 2025 revenue of $0. Revenue peaked in 2022 at $35.4M. The company posted a loss in 2021, 2022, 2023, 2024 and 2025.
In the last 12 months 12 insiders reported 0 open-market purchases and 55 sales ($154.8M). 54 of the sales were made under pre-arranged 10b5-1 plans. The largest was a sale of $18.7M by See Remarks Stephen Michael Kelsey on Sep 15, 2026.
Revolution Medicines filed 11 current reports (Form 8-K) in the last 12 months, most often for results of operations (4), new financial obligation (3), other events (3) and material agreement (2). The latest officer or director change was reported on Jun 22, 2026. It reported a material agreement or a completed acquisition or disposal 2 times.
2 of the 20 investors tracked here held Revolution Medicines at the last quarter end, worth $51.3M combined. It is the largest weight for Duquesne Family Office (1.7% of its portfolio), followed by National Pension Service (Korea) (0%). New this quarter: National Pension Service (Korea). Added: Duquesne Family Office.
Annual results
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net income | -$187M | -$249M | -$436M | -$600M | -$1.13B |
| Diluted EPS | $-2.57 | $-3.08 | $-3.86 | $-3.58 | $-5.95 |
Fiscal year ends Dec 31 · incorporated in DE
Tracked investors holding (13F)
Weight is the share of each investor's portfolio, as of the quarter end.
Current reports (8-K, last 12 months)
Insider open-market trades (last 12 months)
Source: SEC EDGAR. How figures are combined